519 672 2121
519 672 2121
Toggle mobile menu
Book a Consultation
Close mobile menu

Testosterone therapy (or testosterone replacement therapy) is used to treat low testosterone levels, also known as hypogonadism or “low T,” in men. Prescription testosterone is available in several forms, including:

  • injections (Delatestryl or Depo-Testosterone)

  • gels or patches (Androgel)

  • pills (Andriol)

The "testosterone therapy" class action alleged that the defendants failed to adequately warn patients and physicians that the use of testosterone therapy increases the risk of serious cardiovascular side effects, including heart attack, stroke, deep vein thrombosis, pulmonary embolism, and death. Siskinds and Siskinds, Desmeules were representing individuals who have used testosterone therapy and suffered an adverse cardiovascular event.

Siskinds and Siskinds, Desmeules are no longer prosecuting actions related to testosterone therapy. All of the class actions have been discontinued.

Developments

On October 1, 2021, the Ontario Superior Court of Justice issued a judgement discontinuing the proposed Delatestryl class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here (English) and here (French). The discontinuance relates to the proposed Delatestryl class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On July 14, 2021, the Ontario Superior Court of Justice issued a judgement discontinuing the proposed Andriol class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here: EN and FR. The discontinuance relates to the proposed Andriol class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On June 21 2021, the Superior Court of Quebec issued a judgement discontinuing the motion for authorization in the Quebec class action concerning Andriol. A copy of the judgment rendered by the Superior Court of Quebec authorizing the discontinuance is available here. Copy of the notice of discontinuance is available here (English and French). The discontinuance relates to the proposed Andriol class action in Quebec only.

On October 30, 2019, the Ontario Superior Court of Justice issued a judgement discontinuing  the proposed Depo-Testosterone class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here: EN and FR. The discontinuance relates to the proposed Depo-Testosterone class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On November 23, 2016, the Ontario Superior Court of Justice issued a judgement dismissing a proposed class action alleging that AndroGel, a form of testosterone replacement therapy (“TRT”), causes serious cardiovascular events, including heart attacks and strokes. Click here for the reasons the Court dismissed the action.

Documents

On October 1, 2021, the Ontario Superior Court of Justice issued a judgement discontinuing the proposed Delatestryl class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here (English) and here (French). The discontinuance relates to the proposed Delatestryl class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On July 14, 2021, the Ontario Superior Court of Justice issued a judgement discontinuing the proposed Andriol class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here: EN and FR. The discontinuance relates to the proposed Andriol class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On June 21 2021, the Superior Court of Quebec issued a judgement discontinuing the motion for authorization in the Quebec class action concerning Andriol. A copy of the judgment rendered by the Superior Court of Quebec authorizing the discontinuance is available here. Copy of the notice of discontinuance is available here (English and French). The discontinuance relates to the proposed Andriol class action in Quebec only.

On October 30, 2019, the Ontario Superior Court of Justice issued a judgement discontinuing  the proposed Depo-Testosterone class proceeding. A copy of the judgement rendered by the Ontario Superior Court of Justice authorizing the discontinuance, is available here. The Notice of Discontinuance can be found here: EN and FR. The discontinuance relates to the proposed Depo-Testosterone class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products.

On November 23, 2016, the Ontario Superior Court of Justice issued a judgement dismissing a proposed class action alleging that AndroGel, a form of testosterone replacement therapy (“TRT”), causes serious cardiovascular events, including heart attacks and strokes. Click here for the reasons the Court dismissed the action.